Abstract
As tumor mutational burden (TMB) has been approved as a predictive biomarker for immune checkpoint inhibitors (ICIs), next-generation sequencing (NGS)......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
